Opus Genetics to Present at OIS Retina Innovation Summit 2022

RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., president and CEO of Opus, will present at the Ophthalmology Innovation Source (OIS) Retina Innovation Summit 2022 on Wednesday, July 13, 2022, in New York. Dr. Yerxa will deliver a company overview as part of the Innovation Showcase to discuss Opus' unique model of combining validated science and commitment to patient need with wholly owned programs in inherited retinal diseases. Dr. Yerxa will also highlight Opus' lead AAV-based gene therapy programs being developed to address mutations in genes that cause different ... Full story available on Benzinga.com